Atreca, Inc.

Thank you for standing by, and welcome to ATRECA's fourth quarter and year-end 2022 earnings call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. I would now like to hand the call over to Head of Investor Relations, Alex Gray. Please go ahead.

Thank you, Operator, and thank you to those joining us today. We are pleased to host our year-end 2022 conference call and webcast, including updated data from our ongoing Phase 1B trial of ATRC 101. Joining me for the prepared remarks are John Orwin, CEO, Dr. Tito Serafini, Chief Strategy Officer and Atreka founder, Dr. Philippe Bishop, Chief Medical Officer, and Dr. Stephen Gould, Chief Scientific Officer. Also on the line is Herb Cross, Chief Financial Officer, who will be available during the Q&A session. For those joining by phone, I'd note that we are presenting slides as part of today's program, which can be viewed via the webcast link included in our earnings release and posted to the events and presentations section of our investor relations website at ir.otreka.com. An archived replay of today's webcast and the accompanying slides will be available on our IR site following the live presentation. During today's call, we will be making forward-looking statements based on current expectations. These statements are subject to a number of significant risks and uncertainties, and our actual results may differ materially. For a description of risks and factors that could affect our future financial results in business, please refer to the disclosure in the accompanying slides, our most recent Forms 10-K and 10-Q, and the report that we may file on Form 8-K with the Securities and Exchange Commission. All our statements are made as of today, March 29, 2023, based on information currently available to us. We can give no assurance that these statements will prove to be correct. We undertake no duty to update these statements except as required by law. I'll now turn it over to John Orlin. John?

Thank you, Alex. On today's call, TIDA will provide an update on our discovery platform and its evolution. Philippe will present data from the ATRC-101 monotherapy and pembrolizumab combination cohorts in our ongoing Phase 1b trial, and Stephen will then provide an overview of our preclinical pipeline. I will then discuss our financials and upcoming milestones before opening the line for Q&A. Shown on slide four is a broad overview of our platform and pipeline. As a reminder, Matrica has a proprietary platform that enables us to access novel antibodies binding to novel tumor targets that would unlikely be found via traditional discovery approaches. As Tito will discuss in more detail, we have continued to invest in the development of the platform, which has enabled us to find promising antibodies and identify their targets more efficiently. From the platform, we've generated a robust pipeline led by ATRC 101, which, as we'll discuss later, has demonstrated durable anti-tumor activity in the ongoing Phase 1b trial, and which we believe validates the ability of our platform to identify active tumor-targeting antibodies with therapeutic potential. We plan to provide an update on our clinical strategy for ATRC 101, including a go-no-go decision for Phase 2 development by the end of this year. advancing multiple promising preclinical programs, including APN 497444, which targets a novel tumor-specific bican and is advancing as an antibody drug conjugate, as well as APN 346958, which recognizes the cell surface RNA binding protein target and is advancing as a T cell engager in partnership with NCORP. We expect to nominate clinical candidates from both programs later this year. and begin clinical studies for additional oncology programs in 2025. I will now turn it over to Tito to briefly discuss our discovery platform and its evolution before we review the updated ATRC 101 data and preclinical pipeline.